CelLBxHealth (LSE:CLBX), the cancer diagnostics group behind the Parsortix system, said on 21 October 2026 that it expects Revenue growth of 29% this year and between 3.0 million and 4.0 million pounds next year. The same update showed cash of only 1.4 million pounds, which keeps funding at the centre of the Investment case.

What the company does

CelLBxHealth develops liquid biopsy technology. Its Parsortix system captures circulating tumour cells from blood samples, and the company sells instruments, consumables and services to pharmaceutical and academic customers. Recent announcements show that laboratory use remains central: on 3 August 2026 it highlighted Parsortix-harvested cells being used to assess antibody drug conjugate targets, and on 11 August 2026 it highlighted their use in brain cancer detection.

Third-quarter update

The third-quarter trading update and outlook, published on 21 October 2026, forecast full-year 2026 revenue of 1.8 million pounds, 29% higher than in 2025. For 2027 the company expects revenue of 3.0 million to 4.0 million pounds. New Business of 0.3 million pounds was secured, three times the previous year's level.

Cash at the end of September 2026 was 1.4 million pounds, and LSE:CLBX expects an R and D tax Credit of about 0.8 million pounds. The cash operating loss for the year to date fell by about 60% to 4.0 million pounds. On those figures the company projected a cash runway through the first quarter of 2027.

New commercial agreements

Two contract announcements accompanied the trading news. On 14 October 2026 LSE:CLBX announced a new statement of work with a United States pharmaceutical company, and on 21 October 2026 it signed a master services agreement with a Swiss biotechnology company. Master services agreements typically provide a framework under which individual projects are commissioned, so the real revenue contribution will depend on the projects that follow.

Earlier results and board

The company reported preliminary results on 22 June 2026, ahead of its Annual General Meeting on 14 July 2026, and first-half results on 15 July 2026. A directorate change was announced on 6 July 2026, and share Options were issued on 16 July 2026.

Sector and index context

CelLBxHealth (LSE:CLBX) is among the small healthcare technology names on the FTSE AIM All Share Index, a market where loss-making diagnostics developers typically rely on Stock Markets or partners for funding. Demand for tools that measure tumour cells in blood is supported by drug developers seeking better ways to select patients and track response, but adoption by pharmaceutical customers tends to be gradual and project-based.

Key risks

The key risk is liquidity. A cash runway only to the first quarter of 2027 implies that the company must raise capital, secure partner funding or cut costs soon, and a fundraising could dilute existing holders. Revenue of 1.8 million pounds is small against a cash operating loss of 4.0 million pounds in nine months, so the forecast jump in 2027 revenue of at least 3.0 million pounds is the foundation for any path to self-sufficiency. Pharmaceutical contracts can be delayed, reduced or cancelled, and a forecast is not a certainty, and regulatory acceptance of liquid biopsy products remains a long-term uncertainty.

What to watch next

Investors will look for any financing announcement, the full-year results, conversion of the new statement of work and master services agreement into revenue, receipt of the R&D tax credit, and further evidence of Parsortix use in published studies. Progress towards the 2027 revenue range of 3.0 million to 4.0 million pounds will be the main measure of whether the commercial strategy is gaining traction.